Teen battling kidney disease hopes to help other youths with chronic conditionsNew Castle NewsGrace has agreed to try a new drug called Rituximab, which will be given to her intravenously in a one-time, six-hour treatment. She hopes that will help put …
|
North Shore-LIJ Cancer Institute Doctors’ Editorial Published in The New …
PR Web (press release) Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had … |
|
Xencor’s CEO Discusses Q4 2013 Results – Earnings Call Transcript
Seeking Alpha So that’s a potential significant differentiator for safety purposes from cytotoxic B-cell antibodies that are currently used in autoimmune disease such as rituximab. Now, our partner Amgen has an option to acquire the exclusive worldwide license to … |
Medscape |
Obinutuzumab Beats Rituximab in CLL
Medscape The new anti-CD20 antibody obinutuzumab (Gazya) performed better than the older product rituximab (Rituxan) when both were added to chemotherapy in previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities. North Shore-LIJ Cancer Institute doctors’ editorial publishedEurekAlert (press release) |
|
North Shore-LIJ Cancer Institute doctors’ editorial published
EurekAlert (press release) Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had … |
|
New Market Study Published: Investigation Report on China Rituximab Market …
ClickPress (press release) [ClickPress, Mon Mar 17 2014] Rituximab (trade names “MabThera” by Roche, “Rituxan” by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment … |
Idelalisib plus rituximab improves progression-free survival in relapsed CLL2 Minute Medicine1. Idelalisib plus rituximab improved progression-free survival in patients with relapsing CLL compared to rituximab plus placebo. This benefit was seen across…
Clinical Oncology News |
Obinutuzumab Superior to Rituximab in CLL
Clinical Oncology News New Orleans—In previously untreated patients with chronic lymphocytic leukemia and comorbidities, the novel CD20-targeted monoclonal antibody obinutuzumab is more active than rituximab, according to results of a Phase III trial that paired both with … |
Pharmacy Practice News |
Obinutuzumab Superior to Rituximab in CLL
Pharmacy Practice News New Orleans—In previously untreated patients with chronic lymphocytic leukemia and comorbidities, the novel CD20-targeted monoclonal antibody obinutuzumab is more active than rituximab, according to results of a Phase III trial that paired both with … |
|
Research and Markets: Investigation Report on China Rituximab Market, 2009 …
Business Wire (press release) Rituximab (trade names “”MabThera”” by Roche, “”Rituxan”” by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of B-cell lymphoma. |